➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: June 22, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020412

Email this page to a colleague

« Back to Dashboard

NDA 020412 describes ZERIT, which is a drug marketed by Bristol Myers Squibb and Bristol-myers Squibb and is included in three NDAs. There is one patent protecting this drug. Additional details are available on the ZERIT profile page.

The generic ingredient in ZERIT is stavudine. There are fourteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the stavudine profile page.
Summary for 020412
Applicant:Bristol-myers Squibb
Formulation / Manufacturing:see details
Medical Subject Heading (MeSH) Categories for 020412

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE;ORALStrength5MG
Approval Date:Jun 24, 1994TE:RLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE;ORALStrength15MG
Approval Date:Jun 24, 1994TE:RLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE;ORALStrength20MG
Approval Date:Jun 24, 1994TE:RLD:Yes

Expired US Patents for NDA 020412

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bristol-myers Squibb ZERIT stavudine CAPSULE;ORAL 020412-004 Jun 24, 1994   Try Before You Buy   Try Before You Buy
Bristol Myers Squibb ZERIT stavudine CAPSULE;ORAL 020412-001 Jun 24, 1994   Try Before You Buy   Try Before You Buy
Bristol-myers Squibb ZERIT stavudine CAPSULE;ORAL 020412-005 Jun 24, 1994   Try Before You Buy   Try Before You Buy
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.